• Measures of the safety and tolerability of AIR645 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, pulmonary function tests, heart rhythm, and laboratory tests. [ Time Frame: During dosing and for two weeks after dosing ] [ Designated as safety issue: Yes ]
  

• Bioavailability [ Time Frame: During dosing and for two weeks after dosing ] [ Designated as safety issue: No ]
  

Inclusion Criteria*:

• Good General Health (with or without allergic rhinitis and/or controlled asthma)
• Non-smoker for at least 2 years
• Normal lung function (DLCO)
• Able to provide informed consent and to understand and comply with the requirements of the study

Exclusion Criteria*:

• Clinically significant medical history or condition which precludes participation
• Clinically significant ECG abnormality
• Clinically significant VS or PE abnormality
• Clinically significant screening lab abnormality
• Abnormal lung function (FEV1 <80% predicted)
• Respiratory infection within 14 days of randomization
• HBV, HCV, or HIV
• Breastfeeding or pregnant female
• History of alcohol abuse or illicit drug use within past 24 months
• Use of any tobacco or nicotine-containing product within past 6 months
• Use of any herbal supplement, over-the-counter drug, or prescription drug that is not allowed per protocol
• Use of any investigational drug within past 30 days
• Use of any investigational monoclonal antibody or recombinant protein within past 90 days
• Donation of plasma within past 7 days

• Donation or loss of whole blood within past 56 days

  • Simplified list of I/E criteria; unabridged list available upon request.